NASDAQ:DOMH Dominari Q2 2026 Earnings Report $2.10 -0.03 (-1.41%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Dominari EPS ResultsActual EPS-$0.21Consensus EPS -$0.34Beat/MissBeat by +$0.13One Year Ago EPSN/ADominari Revenue ResultsActual Revenue$16.79 millionExpected Revenue$16.79 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/ADominari Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsDominari's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Dominari Earnings HeadlinesDominari Holdings Stock Price HistoryAugust 15, 2026 | investing.comDominari Holdings, Inc.: Dominari Year to Date Revenue Increases by 14% Over 2025August 11, 2026 | finanznachrichten.deFDA Momentum is Building Around NNVC!NanoViricides (NYSE: NNVC) just received regulatory approval to begin a Phase II trial of NV-387 Oral Gummies for Ebola in the DRC, now the country's largest outbreak on record with over 4,100 cases. NV-387 uses a host-mimetic nanoviricide platform designed to trap and neutralize viruses. Noble Capital Markets recently initiated coverage on NNVC with an Outperform rating and a $6 price target.September 4 at 1:00 AM | Smallcaps Daily (Ad)Dominari Year to Date Revenue Increases by 14% Over 2025August 11, 2026 | prnewswire.comNew America Acquisition I Corp. Announces Leadership Transition; Kyle Wool Appointed Chief Executive OfficerAugust 5, 2026 | globenewswire.comDominari Congratulates Powerus on its Multimillion Dollar Contract for Aerial Drone SystemAugust 3, 2026 | prnewswire.comSee More Dominari Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email. Email Address About DominariDominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.View Dominari ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
